{"product_id":"zeria-pestle-analysis","title":"Zeria Pharmaceutical Co. PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eZeria Pharmaceutical Co.'s external landscape—regulatory shifts, aging populations, pricing pressures, and tech-driven R\u0026amp;D—creates both risks and growth levers for investors and strategists. Our concise PESTLE highlights these forces and actionable implications. Purchase the full analysis to get the complete, ready-to-use intelligence for strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJapan drug pricing policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJapan’s biennial NHI price revisions, most recently implemented in 2024, and aggressive cost-containment directly pressure margins on Zeria’s prescription GI, hepatology and allergy portfolios. Policy-mandated cuts for long-listed products and volume-based repricing incentivize continual innovation to offset revenue erosion. Active engagement in cost-effectiveness evaluations—now central to reimbursement decisions—can help protect premium pricing. Policy stability aids planning but increases headwinds for legacy brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory approval dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePMDA standard review averages about 12 months while Sakigake\/priority pathways target reviews near 6 months, significantly accelerating launch in core GI\/hepatic areas. Close alignment with accepted clinical endpoints for GI\/hepatic diseases is critical to secure favorable labeling and avoid additional trials. PMDA often imposes post-marketing RMP\/surveillance obligations that shape resource allocation and timelines. ICH harmonization (eCTD\/M4) eases multi-country filings and dossier reuse.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare budget shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment focus on aging care (65+ at 29.1% in Japan in 2024) can reallocate pharma funds from acute hospital therapies to chronic geriatric treatments. Prevention and outpatient management are prioritized over hospital spend as Japan health expenditure is about 11% of GDP, pressuring cost shifts. Limited reimbursement for consumer healthcare will shift sales mix to prescription and self-pay. Policy pilots on value-based contracts expanded across OECD in 2023–24, opening partnership opportunities for Zeria.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade and supply security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeopolitical tensions and export controls since 2022 have disrupted APIs and excipients, raising import scrutiny and intermittent shortages for Zeria Pharmaceutical Co.; Japan’s 2023–24 industrial policy includes subsidy programs to bolster domestic pharma production capacity.\u003c\/p\u003e\n\u003cp\u003eTariff changes and customs slowdowns can extend lead times by weeks, so diversified supplier networks and partial onshoring are used to reduce political-risk exposure and maintain continuity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGeopolitics: export controls since 2022\u003c\/li\u003e\n\u003cli\u003eJapan policy: 2023–24 subsidies for domestic production\u003c\/li\u003e\n\u003cli\u003eLogistics: customs delays add weeks to lead times\u003c\/li\u003e\n\u003cli\u003eMitigation: diversified suppliers, partial onshoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNational programs on liver disease, H. pylori and allergies raise screening and treatment volumes; H. pylori ~50% globally, NAFLD ~25%, allergic rhinitis 10–30%, expanding eligible patients when campaigns lift diagnosis. Pandemic preparedness can episodically reprioritize funding; collaboration with agencies enhances adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eH. pylori ~50%\u003c\/li\u003e\n\u003cli\u003eNAFLD ~25%\u003c\/li\u003e\n\u003cli\u003eAllergic rhinitis 10–30%\u003c\/li\u003e\n\u003cli\u003eScreening up → addressable market↑\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJapan 2024 NHI cuts and biennial repricing squeeze drug margins; PMDA ~12m reviews\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJapan’s 2024 NHI price cuts and biennial repricing compress margins for Zeria’s GI\/hepatology\/allergy drugs, forcing innovation and cost-effectiveness evidence to sustain premiums. PMDA median review ~12 months (Sakigake ~6), with post‑market RMPs common; 65+ population 29.1% (2024) shifts funding to chronic care. Export controls since 2022 and 2023–24 subsidies for domestic API capacity reshape supply chains.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey datapoint\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNHI revision\u003c\/td\u003e\n\u003ctd\u003e2024 cuts, biennial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePMDA review\u003c\/td\u003e\n\u003ctd\u003eMedian 12m; Sakigake ~6m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDemographics\u003c\/td\u003e\n\u003ctd\u003e65+ 29.1% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply\u003c\/td\u003e\n\u003ctd\u003eExport controls since 2022; subsidies 2023–24\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Zeria Pharmaceutical Co. across six dimensions—Political, Economic, Social, Technological, Environmental and Legal—backed by current trends and data to surface risks and opportunities. Designed for executives and investors, it delivers actionable, region- and industry-specific insights for strategy, scenario planning and funding decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary of Zeria Pharmaceutical Co. that clarifies regulatory, market, economic and technological risks, easily dropped into presentations or shared across teams to speed strategic decision-making and align mitigation actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSlower GDP growth (~1.3% in Japan, IMF 2024) and lingering deflationary pressure (core CPI around 2–3% in 2024) constrain Zeria’s pricing power; JPY volatility (≈¥150–155\/USD in 2024–25) raises raw-material import costs and alters export competitiveness. Consumer healthcare sales track disposable income, while stable defensive prescription demand—with Japan’s pharmaceutical market ≈¥13 trillion (2024)—partially buffers revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging demographics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJapan’s 65+ population reached about 29% in 2024, driving higher prevalence of GI and hepatic conditions and expanding long‑term medication needs for Zeria; rising utilization pressures payers to pursue cost controls and stricter reimbursement; targeted adherence programs (medication support, REMS, digital reminders) can improve outcomes and capture value through reduced complications and better persistence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D productivity and ROI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZeria ties capital allocation to probability of technical and regulatory success in niche GI\/hep assets, where industry Phase I→approval success rates hover near 10%, guiding go\/no‑go decisions.\u003c\/p\u003e\n\u003cp\u003ePartnering and in‑licensing de‑risk pipelines through upfronts and risk‑sharing but typically compress gross margins via royalties commonly in the 10–25% range.\u003c\/p\u003e\n\u003cp\u003eLonger development timelines lift effective cost of capital into the low double digits and raise per‑asset spend (industry estimates around $2.6B per approved drug), so portfolio pruning that trims lower‑probability programs can improve R\u0026amp;D efficiency by roughly 20–30%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric and biosimilar pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatent expiries drive steep price erosion (often 70–90% for small-molecule generics), pressuring mature hepatology segments; Japan reached roughly an 80% generic volume target by 2023. Biosimilar uptake can reshape biologic economics—EU uptake for core biologics often 40–60%, while Japan’s biosimilar value share remained low but rising into the 2020s. Differentiation via formulation or delivery and active lifecycle management help mitigate revenue cliffs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrice erosion: 70–90%\u003c\/li\u003e\n\u003cli\u003eJapan generic volume: ~80% (2023)\u003c\/li\u003e\n\u003cli\u003eEU biosimilar uptake: 40–60% for key biologics\u003c\/li\u003e\n\u003cli\u003eMitigation: formulation\/delivery, lifecycle management\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEnergy, freight and regulatory compliance materially pressure Zeria Pharmaceutical’s COGS; global container rates fell c.70% from 2021 peaks by 2024 but fuel and compliance costs remain elevated, squeezing margins. Nearshoring and dual‑sourcing raise fixed costs but cut disruption risk, while higher inventory levels lock up working capital; lean operations defend EBITDA.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCOGS: energy, freight, compliance\u003c\/li\u003e\n\u003cli\u003eNearshoring\/dual‑sourcing: higher fixed cost, lower disruption\u003c\/li\u003e\n\u003cli\u003eInventory: ties up working capital\u003c\/li\u003e\n\u003cli\u003eLean ops: protect EBITDA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJapan 2024 NHI cuts and biennial repricing squeeze drug margins; PMDA ~12m reviews\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSlower GDP (~1.3% Japan, IMF 2024) and core CPI 2–3% limit pricing; JPY ~¥150–155\/USD raises import costs while Japan’s ¥13T pharma market and 29% 65+ population sustain prescription demand. Patent cliffs (70–90% price erosion) and ~80% generic volume (2023) compress revenues; biosimilars slowly rising. R\u0026amp;D costs (~$2.6B\/approval) and ~10% success rates force selective investing and partnerships (royalties 10–25%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDP growth (Japan)\u003c\/td\u003e\n\u003ctd\u003e~1.3% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore CPI\u003c\/td\u003e\n\u003ctd\u003e2–3% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJPY\u003c\/td\u003e\n\u003ctd\u003e¥150–155\/USD (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma market\u003c\/td\u003e\n\u003ctd\u003e≈¥13T (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e65+ population\u003c\/td\u003e\n\u003ctd\u003e~29% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent erosion\u003c\/td\u003e\n\u003ctd\u003e70–90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric volume\u003c\/td\u003e\n\u003ctd\u003e~80% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval cost\u003c\/td\u003e\n\u003ctd\u003e~$2.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase→approval success\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical royalties\u003c\/td\u003e\n\u003ctd\u003e10–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eZeria Pharmaceutical Co. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThis PESTLE analysis examines political, economic, social, technological, legal, and environmental factors shaping Zeria Pharmaceutical Co., highlighting risks and strategic opportunities. The preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. No placeholders, ready to download and apply immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162645377401,"sku":"zeria-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/zeria-pestle-analysis.png?v=1762705372","url":"https:\/\/portersfiveforce.com\/products\/zeria-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}